Kolexia
Damaj Ghandi Laurent
Hématologie
Hôpital Côte de Nacre
Caen, France
140 Activités
0 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Mastocytose Lymphome T Lymphome à cellules du manteau Lymphome B Lymphome B diffus à grandes cellules Lymphome T périphérique Leucémies Lymphome folliculaire

Industries

Takeda Pharmaceutical
21 collaboration(s)
Dernière en 2023
Amgen
11 collaboration(s)
Dernière en 2023
Novartis
7 collaboration(s)
Dernière en 2023
Abbvie
6 collaboration(s)
Dernière en 2023

Dernières activités

LyMa101: Phase II Study to Evaluate the Efficacy of Upfront Obinutuzumab in Mantle Cell Lymphoma Patients Treated by DHAP Followed by Autologous Transplantation Plus Obinutuzumab Maintenance Then MRD Driven Maintenance
Essai Clinique (The Lymphoma Academic Research Organisation)   13 mars 2024
RAT-HEMATO : Return to Work After Malignant Hemopathy
Essai Clinique (CHU Angers)   13 février 2024
Study of Lacutamab in Peripheral T-cell Lymphoma: A Randomized Non Comparative Phase II Study of Lacutamab With GemOx Versus GemOx Alone in Relapsed/Refractory Patients With Peripheral T-cell Lymphoma
Essai Clinique (Innate Pharma)   04 décembre 2023
L’éosinophile et ses interactions avec le mastocyte dans la mastocytose non avancée : vers un ciblage thérapeutique de l’interleukine 5 et/ou son récepteur ?
87e CONGRÈS FRANÇAIS DE MÉDECINE INTERNE   01 décembre 2023
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Haematologica   30 novembre 2023
Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes.
The Journal of allergy and clinical immunology   24 août 2023
Quality of life and response shift effect of diffuse large B-cell lymphoma French patients included in prospective real-life REALYSA cohort in the first year after diagnosis
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 ‐ 17 June, 2023   09 juin 2023
Allogeneic transplantation in T-cell lymphoma: Lessons from the AATT study
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 ‐ 17 June, 2023   09 juin 2023
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in elderly mantle cell lymphoma patients. For the LYSA group.
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 ‐ 17 June, 2023   09 juin 2023
ROMIDEPSIN PLUS CHOP VERSUS CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T-CELL LYMPHOMA: FINAL ANALYSIS OF THE RO-CHOP TRIAL
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 ‐ 17 June, 2023   09 juin 2023